FI930753A0 - Nya fosfolipidderivat av nukleosider, deras framstaellning och deras anvaendning saosom antivirala laekemedel - Google Patents

Nya fosfolipidderivat av nukleosider, deras framstaellning och deras anvaendning saosom antivirala laekemedel

Info

Publication number
FI930753A0
FI930753A0 FI930753A FI930753A FI930753A0 FI 930753 A0 FI930753 A0 FI 930753A0 FI 930753 A FI930753 A FI 930753A FI 930753 A FI930753 A FI 930753A FI 930753 A0 FI930753 A0 FI 930753A0
Authority
FI
Finland
Prior art keywords
deras
phospholipidderivat
nucleosider
antivirala
laekemedel
Prior art date
Application number
FI930753A
Other languages
English (en)
Other versions
FI930753A (fi
FI104176B (fi
FI104176B1 (fi
Inventor
Harald Zilch
Herbert Leinert
Alfred Mertens
Dieter Herrmann
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25896049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI930753(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of FI930753A publication Critical patent/FI930753A/fi
Publication of FI930753A0 publication Critical patent/FI930753A0/fi
Application granted granted Critical
Publication of FI104176B publication Critical patent/FI104176B/fi
Publication of FI104176B1 publication Critical patent/FI104176B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
FI930753A 1990-08-20 1993-02-19 Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi FI104176B1 (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE4026265A DE4026265A1 (de) 1990-08-20 1990-08-20 Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
DE4026265 1990-08-20
EP9101541 1991-08-14
PCT/EP1991/001541 WO1992003462A1 (de) 1990-08-20 1991-08-14 Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US66103896 1996-06-10
US08/661,038 US5756711A (en) 1990-08-20 1996-06-10 Phospholipid derivatives of nucleosides and their use as anti-viral medicaments

Publications (4)

Publication Number Publication Date
FI930753A FI930753A (fi) 1993-02-19
FI930753A0 true FI930753A0 (fi) 1993-02-19
FI104176B FI104176B (fi) 1999-11-30
FI104176B1 FI104176B1 (fi) 1999-11-30

Family

ID=25896049

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930753A FI104176B1 (fi) 1990-08-20 1993-02-19 Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi

Country Status (15)

Country Link
US (1) US5756711A (fi)
EP (1) EP0545966B1 (fi)
CN (1) CN1032258C (fi)
AT (1) ATE114316T1 (fi)
CA (1) CA2090024C (fi)
DE (2) DE4026265A1 (fi)
DK (1) DK0545966T3 (fi)
ES (1) ES2066461T3 (fi)
FI (1) FI104176B1 (fi)
HK (1) HK35597A (fi)
IE (1) IE64374B1 (fi)
NO (1) NO179710C (fi)
PT (1) PT98720B (fi)
SK (1) SK281826B6 (fi)
WO (1) WO1992003462A1 (fi)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
DE4204032A1 (de) * 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
DE4204031A1 (de) * 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
DE4226279A1 (de) * 1992-08-08 1994-02-10 Boehringer Mannheim Gmbh Liponucleotide von Seco-Nucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
US6080734A (en) * 1992-08-08 2000-06-27 Roche Diagnostic Gmbh Liponucleotides of seco-nucleosides, their production as well as their use as antiviral pharmaceutical agents
ATE226437T1 (de) * 1993-06-10 2002-11-15 Univ Wake Forest (phospho)lipide zum bekämpfen einer hepatitis b- infektion
KR0125779B1 (ko) * 1993-12-04 1997-12-19 김승호 뉴클레오시드 화합물 및 이의 제조방법
DE4418690A1 (de) * 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
US5962437A (en) 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
PT791056E (pt) * 1994-11-12 2005-08-31 Heidelberg Pharma Gmbh Enzima de degradacao de lipidos
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
DE19547022A1 (de) * 1995-12-15 1997-06-19 Boehringer Mannheim Gmbh Kovalente Lipid-Phosphonocarbonsäure-Konjugate, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
TW343975B (en) * 1995-12-15 1998-11-01 Boehringer Mannheim Gmbh New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
DE19602757A1 (de) 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
AU2001291173A1 (en) 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
IL160080A0 (en) 2001-08-31 2004-06-20 Thomson Licensing Sa Sequence counter for an audio visual stream
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
DE10156910A1 (de) * 2001-11-21 2003-06-05 Heidelberg Pharma Holding Gmbh Phospholipid-Derivate von Nucleosiden als antitumorale Arzneimittel
AU2002356672A1 (en) * 2001-11-21 2003-06-10 Ganymed 256 Vermogensverwaltungs Gmbh Phospholipid derivitives of nucleosides as antitumoral medicaments
EP1460082A1 (en) 2003-03-19 2004-09-22 Heidelberg Pharma Holding GmbH Phospholipid esters of clofarabine derivatives
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2006066074A2 (en) * 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
EA011039B1 (ru) 2004-12-30 2008-12-30 Медивир Аб Приемлемые для лечения вич соединения
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
US20070003608A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
GB0608876D0 (en) 2006-05-05 2006-06-14 Medivir Ab Combination therapy
US7378401B2 (en) 2006-07-14 2008-05-27 Heidelberg Pharma Gmbh Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
MX2010003002A (es) 2007-09-26 2010-07-05 Sinai School Medicine Analogos de azacitidina y sus usos.
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
EP2070938A1 (en) 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
MX2010007418A (es) * 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5562255B2 (ja) * 2008-01-25 2014-07-30 キメリクス，インコーポレイテッド ウイルス感染を治療する方法
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
NZ590258A (en) * 2008-07-08 2013-10-25 Intellikine Llc Kinase inhibitors and methods of use
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PT2970346T (pt) 2013-03-15 2018-11-09 Univ California Diésteres de fosfonato nucleosídico acíclico
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
BR112017005111B1 (pt) 2014-09-15 2023-02-14 The Regents Of The University Of California Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
CN105288648B (zh) * 2015-10-14 2018-11-06 东南大学 一种亲水性药物的磷脂化合物、其药物组合物及应用
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
DE112020006626A5 (de) 2020-03-30 2022-12-08 Chiracon Gmbh Fosalvudin und Fozivudintidoxil zur Anwendung bei der Behandlung der Krankheit Covid-19 und die Verwendung von deren strukturvereinfachten Derivaten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
US4283394A (en) * 1979-08-06 1981-08-11 Research Corporation Cytotoxic nucleoside-corticosteroid phosphodiesters
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0262876B1 (en) * 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use

Also Published As

Publication number Publication date
AU654670B2 (en) 1994-11-17
NO930587D0 (no) 1993-02-19
EP0545966A1 (de) 1993-06-16
HK35597A (en) 1997-03-27
AU8325191A (en) 1992-03-17
WO1992003462A1 (de) 1992-03-05
CA2090024A1 (en) 1992-02-21
FI930753A (fi) 1993-02-19
SK281826B6 (sk) 2001-08-06
PT98720A (pt) 1992-07-31
EP0545966B1 (de) 1994-11-23
SK9293A3 (en) 1993-07-07
NO179710B (no) 1996-08-26
DK0545966T3 (da) 1995-05-08
ATE114316T1 (de) 1994-12-15
DE4026265A1 (de) 1992-02-27
IE912930A1 (en) 1992-02-26
FI104176B (fi) 1999-11-30
NO930587L (no) 1993-02-19
CN1032258C (zh) 1996-07-10
PT98720B (pt) 1999-02-26
IE64374B1 (en) 1995-07-26
DE59103595D1 (de) 1995-01-05
CN1059149A (zh) 1992-03-04
ES2066461T3 (es) 1995-03-01
FI104176B1 (fi) 1999-11-30
US5756711A (en) 1998-05-26
NO179710C (no) 1996-12-04
CA2090024C (en) 2000-05-02

Similar Documents

Publication Publication Date Title
FI930753A (fi) Nya fosfolipidderivat av nukleosider, deras framstaellning och deras anvaendning saosom antivirala laekemedel
IL89921A0 (en) 1,3-dioxolane derivatives and pharmaceutical compositions containing the same
NZ300073A (en) Substituted arythio derivatives; medicaments; used as antibacterial and antiviral agents
ATE125817T1 (de) Antivirale verbindungen.
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2164639T3 (es) Quinoxalinas, procedimiento para su preparacion y su empleo.
KR910700089A (ko) 히드로클로로플루오로프로판의 공비 조성물 또는 공비형 조성물
FI883667A0 (fi) 2-/(4-piperidinyl) metyl/ -1,2,3,4-tetrahydroisokinoleinderivat, deras framstaellning och terapeutiska anvaendning.
DE3028340C2 (fi)
FI881609A0 (fi) Dihydropyridinamider, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2102772T3 (es) Compuesto citotoxico y antiviral.
EP0331092A3 (en) Alpha-amino-carboxylic-acid derivatives, their preparation and use
DK319785D0 (da) Acetyleniske phenoxypropanolderivater
ES2123739T3 (es) Nuevos analogos del eburnano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE69007775D1 (de) 5'-alkylphosphonylnukleoside als antivirale verbindungen.
SE9203824D0 (sv) Benzofuranylimidazole derivatives a process for the preparation and therapeutical compositions containing the same
IT8721457A0 (it) Composizioni farmaceutiche antivirali.
NO910607D0 (no) Fremgangsmaate for fremstilling av 3'-fluor-nukleosidanaloger.
FI911616A (fi) Substituerade 3-tia- eller 3-oxa-alkyl -flavoner, foerfarande foer deras framstaellning, deras anvaendning, pao dessa foereningar baserade laekemedel samt mellanprodukter.
ES2103553T3 (es) Nuevos cicloalquil-(b)-indoles, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
FI880063A0 (fi) Nya derivat av 4,4-dimetyl tetrahydropyr-2-on, foerfarande foer deras framstaellning och deras anvaendning vid syntes av pyretinoidfoereningar.
IT8621925A0 (it) Composizioni farmaceutiche adattivita' antineoplastica.

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH